Login Register Cart 0
Generic placeholder image

Protein & Peptide Letters

Editor-in-Chief

ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review

Author(s): Brigida Anna Maiorano, Giovanni Schinzari, Sabrina Chiloiro, Felicia Visconti, Domenico Milardi and Antonio Bianchi*

Volume 27, Issue 12, 2020

Page: [1276 - 1287] Pages: 12

DOI: 10.2174/0929866527666200504122116

Price: $65

Abstract

Pancreatic neuroendocrine tumors (PanNETs) are rare tumors having usually an indolent behavior, but sometimes with unpredictable aggressiveness. PanNETs are more often non-functioning (NF), unable to produce functioning hormones, while 10-30% present as functioning (F) - PanNETs, such as insulinomas , gastrinomas , and other rare tumors. Diagnostic and prognostic markers, but also new therapeutic targets, are still lacking. Proteomics techniques represent therefore promising approaches for the future management of PanNETs. We conducted a systematic review to summarize the state of the art of proteomics in PanNETs. A total of 9 studies were included, focusing both on NF- and F-PanNETs. Indeed, proteomics is useful for the diagnosis, the prognosis and the detection of therapeutic targets. However, further studies are required. It is also warranted to standardize the analysis methods and the collection techniques, in order to validate proteins with a relevance in the personalized approach to PanNETs management.

Keywords: Proteomics, pancreatic neuroendocrine tumors, non-functioning, insulinoma, neuroendocrine neoplasms, proteomic profiling.

« Previous Next »
Graphical Abstract

[1]
Cives, M.; Strosberg, J.R. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin., 2018, 68(6), 471-487.
[http://dx.doi.org/10.3322/caac.21493] [PMID: 30295930]
[2]
Fraenkel, M.; Faggiano, A.; Valk, G.D. Epidemiology of neuroendocrine tumors. Front. Horm. Res., 2015, 44, 1-23.
[http://dx.doi.org/10.1159/000381970] [PMID: 26303701]
[3]
Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26(18), 3063-3072.
[http://dx.doi.org/10.1200/JCO.2007.15.4377] [PMID: 18565894]
[4]
Lloyd, R.V.; Osamura, R.Y.; Kloppel, G.; Rosai, J. WHO Classification of Tumours of Endocrine Organs. WHO/IARC Classification of Tumours, 4th ed; IARC Press: Lyon, France, 2017, Vol. 10.
[5]
Yang, M.; Tian, B.L.; Zhang, Y.; Su, A.P.; Yue, P.J.; Xu, S.; Wang, L. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. Pancreas, 2014, 43(7), 1003-1008.
[http://dx.doi.org/10.1097/MPA.0000000000000153] [PMID: 24945681]
[6]
Jensen, R.T.; Berna, M.J.; Bingham, D.B.; Norton, J.A. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer, 2008, 113(7)(Suppl.), 1807-1843.
[http://dx.doi.org/10.1002/cncr.23648] [PMID: 18798544]
[7]
Anlauf, M.; Garbrecht, N.; Bauersfeld, J.; Schmitt, A.; Henopp, T.; Komminoth, P.; Heitz, P.U.; Perren, A.; Klöppel, G. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch., 2007, 451(Suppl. 1), S29-S38.
[http://dx.doi.org/10.1007/s00428-007-0450-3] [PMID: 17684762]
[8]
Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell. Endocrinol., 2014, 386(1-2), 2-15.
[http://dx.doi.org/10.1016/j.mce.2013.08.002] [PMID: 23933118]
[9]
Chiloiro, S.; Lanza, F.; Bianchi, A.; Schinzari, G.; Brizi, M.G.; Giampietro, A.; Rufini, V.; Inzani, F.; Giordano, A.; Rindi, G.; Pontecorvi, A.; De Marinis, L. Pancreatic neuroendocrine tumors in MEN1 disease: A mono-centric longitudinal and prognostic study. Endocrine, 2018, 60(2), 362-367.
[http://dx.doi.org/10.1007/s12020-017-1327-0] [PMID: 28567607]
[10]
Rednam, S.P.; Erez, A.; Druker, H.; Janeway, K.A.; Kamihara, J.; Kohlmann, W.K.; Nathanson, K.L.; States, L.J.; Tomlinson, G.E.; Villani, A.; Voss, S.D.; Schiffman, J.D.; Wasserman, J.D. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin. Cancer Res., 2017, 23(12), e68-e75.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0547] [PMID: 28620007]
[11]
Dworakowska, D.; Grossman, A.B. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr. Relat. Cancer, 2009, 16(1), 45-58.
[http://dx.doi.org/10.1677/ERC-08-0142] [PMID: 18978035]
[12]
Rogers, A.; Wang, L.M.; Karavitaki, N.; Grossman, A.B. Neurofibromatosis Type 1 and pancreatic islet cell tumours: An association which should be recognized. QJM, 2015, 108(7), 573-576.
[http://dx.doi.org/10.1093/qjmed/hcs203] [PMID: 23173186]
[13]
Falconi, M.; Plockinger, U.; Kwekkeboom, D.J.; Manfredi, R.; Korner, M.; Kvols, L.; Pape, U.F.; Ricke, J.; Goretzki, P.E.; Wildi, S.; Steinmuller, T.; Oberg, K.; Scoazec, J.Y. Frascati Consensus Conference; European Neuroendocrine Tumor Society. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology, 2006, 84(3), 196-211.
[http://dx.doi.org/10.1159/000098012] [PMID: 17312380]
[14]
Panzuto, F.; Nasoni, S.; Falconi, M.; Corleto, V.D.; Capurso, G.; Cassetta, S.; Di Fonzo, M.; Tornatore, V.; Milione, M.; Angeletti, S.; Cattaruzza, M.S.; Ziparo, V.; Bordi, C.; Pederzoli, P.; Delle Fave, G. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer, 2005, 12(4), 1083-1092.
[http://dx.doi.org/10.1677/erc.1.01017] [PMID: 16322345]
[15]
Crippa, S.; Partelli, S.; Zamboni, G.; Scarpa, A.; Tamburrino, D.; Bassi, C.; Pederzoli, P.; Falconi, M. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery, 2014, 155(1), 145-153.
[http://dx.doi.org/10.1016/j.surg.2013.08.002] [PMID: 24646958]
[16]
Birnbaum, D.J.; Gaujoux, S.; Cherif, R.; Dokmak, S.; Fuks, D.; Couvelard, A.; Vullierme, M.P.; Ronot, M.; Ruszniewski, P.; Belghiti, J.; Sauvanet, A. Sporadic nonfunctioning pancreatic neuroendocrine tumors: Prognostic significance of incidental diagnosis. Surgery, 2014, 155(1), 13-21.
[http://dx.doi.org/10.1016/j.surg.2013.08.007] [PMID: 24238123]
[17]
Service, F.J.; McMahon, M.M.; O’Brien, P.C.; Ballard, D.J. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: A 60-year study. Mayo Clin. Proc., 1991, 66(7), 711-719.
[http://dx.doi.org/10.1016/S0025-6196(12)62083-7] [PMID: 1677058]
[18]
Jensen, R.T. Gastrinomas: Advances in diagnosis and management. Neuroendocrinology, 2004, 80(Suppl. 1), 23-27.
[http://dx.doi.org/10.1159/000080736] [PMID: 15477712]
[19]
Verner, J.V.; Morrison, A.B. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am. J. Med., 1958, 25(3), 374-380.
[http://dx.doi.org/10.1016/0002-9343(58)90075-5] [PMID: 13571250]
[20]
Öberg, K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg., 2018, 7(1), 20-27.
[http://dx.doi.org/10.21037/gs.2017.10.08] [PMID: 29629316]
[21]
Partelli, S.; Bartsch, D.K.; Capdevila, J.; Chen, J.; Knigge, U.; Niederle, B.; Nieveen van Dijkum, E.J.M.; Pape, U.F.; Pascher, A.; Ramage, J.; Reed, N.; Ruszniewski, P.; Scoazec, J.Y.; Toumpanakis, C.; Kianmanesh, R.; Falconi, M. Antibes Consensus Conference participants. Antibes Consensus Conference participants. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology, 2017, 105(3), 255-265.
[http://dx.doi.org/10.1159/000464292] [PMID: 28237989]
[22]
Lee, L.C.; Grant, C.S.; Salomao, D.R.; Fletcher, J.G.; Takahashi, N.; Fidler, J.L.; Levy, M.J.; Huebner, M. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): Role for nonoperative management. Surgery, 2012, 152(6), 965-974.
[http://dx.doi.org/10.1016/j.surg.2012.08.038] [PMID: 23102679]
[23]
Theodoropoulou, M.; Stalla, G.K. Somatostatin receptors: From signaling to clinical practice. Front. Neuroendocrinol., 2013, 34(3), 228-252.
[http://dx.doi.org/10.1016/j.yfrne.2013.07.005] [PMID: 23872332]
[24]
Imhof, A.; Brunner, P.; Marincek, N.; Briel, M.; Schindler, C.; Rasch, H.; Mäcke, H.R.; Rochlitz, C.; Müller-Brand, J.; Walter, M.A. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol., 2011, 29(17), 2416-2423.
[http://dx.doi.org/10.1200/JCO.2010.33.7873] [PMID: 21555692]
[25]
Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26(13), 2124-2130.
[http://dx.doi.org/10.1200/JCO.2007.15.2553] [PMID: 18445841]
[26]
Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Martinez, S.; Blumberg, J.; Ruszniewski, P. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med., 2014, 371(3), 224-233.
[http://dx.doi.org/10.1056/NEJMoa1316158] [PMID: 25014687]
[27]
Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Martinez, S.; Gomez-Panzani, E.; Ruszniewski, P. CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study. Endocr. Relat. Cancer, 2016, 23(3), 191-199.
[http://dx.doi.org/10.1530/ERC-15-0490] [PMID: 26743120]
[28]
Rinke, A.; Müller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Bläker, M.; Harder, J.; Arnold, C.; Gress, T.; Arnold, R. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol., 2009, 27(28), 4656-4663.
[http://dx.doi.org/10.1200/JCO.2009.22.8510] [PMID: 19704057]
[29]
Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.; Tomassetti, P.; Pavel, M.E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Öberg, K. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364(6), 514-523.
[http://dx.doi.org/10.1056/NEJMoa1009290] [PMID: 21306238]
[30]
Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet, 2016, 387(10022), 968-977.
[http://dx.doi.org/10.1016/S0140-6736(15)00817-X] [PMID: 26703889]
[31]
Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hörsch, D.; Winkler, R.E.; Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.; Öberg, K.; Van Cutsem, E.; Yao, J.C. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet, 2011, 378(9808), 2005-2012.
[http://dx.doi.org/10.1016/S0140-6736(11)61742-X] [PMID: 22119496]
[32]
Strosberg, J.R.; Cheema, A.; Weber, J.; Han, G.; Coppola, D.; Kvols, L.K. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J. Clin. Oncol., 2011, 29(22), 3044-3049.
[http://dx.doi.org/10.1200/JCO.2011.35.1817] [PMID: 21709192]
[33]
Frilling, A.; Modlin, I.M.; Kidd, M.; Russell, C.; Breitenstein, S.; Salem, R.; Kwekkeboom, D.; Lau, W.Y.; Klersy, C.; Vilgrain, V.; Davidson, B.; Siegler, M.; Caplin, M.; Solcia, E.; Schilsky, R. Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol., 2014, 15(1), e8-e21.
[http://dx.doi.org/10.1016/S1470-2045(13)70362-0] [PMID: 24384494]
[34]
Panzuto, F.; Boninsegna, L.; Fazio, N.; Campana, D.; Pia Brizzi, M.; Capurso, G.; Scarpa, A.; De Braud, F.; Dogliotti, L.; Tomassetti, P.; Delle Fave, G.; Falconi, M. Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progression. J. Clin. Oncol., 2011, 29(17), 2372-2377.
[http://dx.doi.org/10.1200/JCO.2010.33.0688] [PMID: 21555696]
[35]
Cadiot, G.; Vuagnat, A.; Doukhan, I.; Murat, A.; Bonnaud, G.; Delemer, B.; Thiéfin, G.; Beckers, A.; Veyrac, M.; Proye, C.; Ruszniewski, P.; Mignon, M. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology, 1999, 116(2), 286-293.
[http://dx.doi.org/10.1016/S0016-5085(99)70124-1] [PMID: 9922308]
[36]
Scarpa, A.; Chang, D.K.; Nones, K.; Corbo, V.; Patch, A.M.; Bailey, P.; Lawlor, R.T.; Johns, A.L.; Miller, D.K.; Mafficini, A.; Rusev, B.; Scardoni, M.; Antonello, D.; Barbi, S.; Sikora, K.O.; Cingarlini, S.; Vicentini, C.; McKay, S.; Quinn, M.C.; Bruxner, T.J.; Christ, A.N.; Harliwong, I.; Idrisoglu, S.; McLean, S.; Nourse, C.; Nourbakhsh, E.; Wilson, P.J.; Anderson, M.J.; Fink, J.L.; Newell, F.; Waddell, N.; Holmes, O.; Kazakoff, S.H.; Leonard, C.; Wood, S.; Xu, Q.; Nagaraj, S.H.; Amato, E.; Dalai, I.; Bersani, S.; Cataldo, I.; Dei Tos, A.P.; Capelli, P.; Davì, M.V.; Landoni, L.; Malpaga, A.; Miotto, M.; Whitehall, V.L.; Leggett, B.A.; Harris, J.L.; Harris, J.; Jones, M.D.; Humphris, J.; Chantrill, L.A.; Chin, V.; Nagrial, A.M.; Pajic, M.; Scarlett, C.J.; Pinho, A.; Rooman, I.; Toon, C.; Wu, J.; Pinese, M.; Cowley, M.; Barbour, A.; Mawson, A.; Humphrey, E.S.; Colvin, E.K.; Chou, A.; Lovell, J.A.; Jamieson, N.B.; Duthie, F.; Gingras, M.C.; Fisher, W.E.; Dagg, R.A.; Lau, L.M.; Lee, M.; Pickett, H.A.; Reddel, R.R.; Samra, J.S.; Kench, J.G.; Merrett, N.D.; Epari, K.; Nguyen, N.Q.; Zeps, N.; Falconi, M.; Simbolo, M.; Butturini, G.; Van Buren, G.; Partelli, S.; Fassan, M.; Khanna, K.K.; Gill, A.J.; Wheeler, D.A.; Gibbs, R.A.; Musgrove, E.A.; Bassi, C.; Tortora, G.; Pederzoli, P.; Pearson, J.V.; Waddell, N.; Biankin, A.V.; Grimmond, S.M. Australian Pancreatic Cancer Genome Initiative. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543(7643), 65-71.
[http://dx.doi.org/10.1038/nature21063] [PMID: 28199314]
[37]
Marinoni, I.; Kurrer, A.S.; Vassella, E.; Dettmer, M.; Rudolph, T.; Banz, V.; Hunger, F.; Pasquinelli, S.; Speel, E.J.; Perren, A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology, 2014, 146(2), 453-60.e5.
[http://dx.doi.org/10.1053/j.gastro.2013.10.020] [PMID: 24148618]
[38]
Singhi, A.D.; Liu, T.C.; Roncaioli, J.L.; Cao, D.; Zeh, H.J.; Zureikat, A.H.; Tsung, A.; Marsh, J.W.; Lee, K.K.; Hogg, M.E.; Bahary, N.; Brand, R.E.; McGrath, K.M.; Slivka, A.; Cressman, K.L.; Fuhrer, K.; O’Sullivan, R.J. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin. Cancer Res., 2017, 23(2), 600-609.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1113] [PMID: 27407094]
[39]
Jensen, R.T.; Niederle, B.; Mitry, E.; Ramage, J.K.; Steinmuller, T.; Lewington, V.; Scarpa, A.; Sundin, A.; Perren, A.; Gross, D.; O’Connor, J.M.; Pauwels, S.; Kloppel, G. Frascati Consensus Conference; European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology, 2006, 84(3), 173-182.
[http://dx.doi.org/10.1159/000098009] [PMID: 17312377]
[40]
Jonkers, Y.M.; Claessen, S.M.; Perren, A.; Schmitt, A.M.; Hofland, L.J.; de Herder, W.; de Krijger, R.R.; Verhofstad, A.A.; Hermus, A.R.; Kummer, J.A.; Skogseid, B.; Volante, M.; Voogd, A.C.; Ramaekers, F.C.; Speel, E.J. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocr. Relat. Cancer, 2007, 14(3), 769-779.
[http://dx.doi.org/10.1677/ERC-07-0111] [PMID: 17914106]
[41]
Jensen, R.T.; Bodei, L.; Capdevila, J.; Couvelard, A.; Falconi, M.; Glasberg, S.; Kloppel, G.; Lamberts, S.; Peeters, M.; Rindi, G.; Rinke, A.; Rothmund, M.; Sundin, A.; Welin, S.; Fazio, N. The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet needs in functional and nonfunctional Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 108(1), 26-36.
[http://dx.doi.org/10.1159/000494258] [PMID: 30282083]
[42]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7), e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[43]
Caprioli, R.M.; Farmer, T.B.; Gile, J. Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal. Chem., 1997, 69(23), 4751-4760.
[http://dx.doi.org/10.1021/ac970888i] [PMID: 9406525]
[44]
Casadonte, R.; Kriegsmann, M.; Perren, A.; Baretton, G.; Deininger, S.O.; Kriegsmann, K.; Welsch, T.; Pilarsky, C.; Kriegsmann, J. Development of a class prediction model to discriminate pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumor by MALDI mass spectrometry imaging. Proteomics Clin. Appl., 2019, 13, 1-1800046.
[http://dx.doi.org/10.1002/prca.201800046]
[45]
Willingham, S.B.; Volkmer, J.P.; Gentles, A.J.; Sahoo, D.; Dalerba, P.; Mitra, S.S.; Wang, J.; Contreras-Trujillo, H.; Martin, R.; Cohen, J.D.; Lovelace, P.; Scheeren, F.A.; Chao, M.P.; Weiskopf, K.; Tang, C.; Volkmer, A.K.; Naik, T.J.; Storm, T.A.; Mosley, A.R.; Edris, B.; Schmid, S.M.; Sun, C.K.; Chua, M.S.; Murillo, O.; Rajendran, P.; Cha, A.C.; Chin, R.K.; Kim, D.; Adorno, M.; Raveh, T.; Tseng, D.; Jaiswal, S.; Enger, P.Ø.; Steinberg, G.K.; Li, G.; So, S.K.; Majeti, R.; Harsh, G.R.; van de Rijn, M.; Teng, N.N.; Sunwoo, J.B.; Alizadeh, A.A.; Clarke, M.F.; Weissman, I.L. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA, 2012, 109(17), 6662-6667.
[http://dx.doi.org/10.1073/pnas.1121623109] [PMID: 22451913]
[46]
Jaiswal, S.; Jamieson, C.H.; Pang, W.W.; Park, C.Y.; Chao, M.P.; Majeti, R.; Traver, D.; van Rooijen, N.; Weissman, I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 2009, 138(2), 271-285.
[http://dx.doi.org/10.1016/j.cell.2009.05.046] [PMID: 19632178]
[47]
Krampitz, G.W.; George, B.M.; Willingham, S.B.; Volkmer, J.P.; Weiskopf, K.; Jahchan, N.; Newman, A.M.; Sahoo, D.; Zemek, A.J.; Yanovsky, R.L.; Nguyen, J.K.; Schnorr, P.J.; Mazur, P.K.; Sage, J.; Longacre, T.A.; Visser, B.C.; Poultsides, G.A.; Norton, J.A.; Weissman, I.L. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc. Natl. Acad. Sci. USA, 2016, 113(16), 4464-4469.
[http://dx.doi.org/10.1073/pnas.1600007113] [PMID: 27035983]
[48]
Gong, J.; Blais, E.M.; Bender, J.R.; Guan, M.; Placencio-Hickok, V.; Petricoin, E.F.; Pishvaian, M.J.; Gregory, G.; Tuli, R.; Hendifar, A.E. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Oncotarget, 2019, 10(58), 6260-6268.
[http://dx.doi.org/10.18632/oncotarget.27265] [PMID: 31692857]
[49]
Liu, B.; Tang, L.H.; Liu, Z.; Mei, M.; Yu, R.; Dhall, D.; Qiao, X.W.; Zhang, T.P.; Zhao, Y.P.; Liu, T.H.; Xiao, Y.; Chen, J.; Xiang, H.D.; Wu, H.Y.; Lu, C.M.; Lv, B.; Zhou, Y.R.; Zhang, Y.; Deng, D.; Chen, Y.J. α-Internexin: A novel biomarker for pancreatic neuroendocrine tumor aggressiveness. J. Clin. Endocrinol. Metab., 2014, 99(5), E786-E795.
[http://dx.doi.org/10.1210/jc.2013-2874] [PMID: 24483152]
[50]
Gorman, A.M.; Healy, S.J.M.; Jäger, R.; Samali, A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol. Ther., 2012, 134(3), 306-316.
[http://dx.doi.org/10.1016/j.pharmthera.2012.02.003] [PMID: 22387231]
[51]
Klieser, E.; Illig, R.; Státtner, S.; Primavesi, F.; Jáger, T.; Swierczynski, S.; Kiesslich, T.; Kemmerling, R.; Bollmann, C.; Di Fazio, P.; Neureiter, D. Endoplasmic reticulum stress in pancreatic neuroendocrine tumors is linked to clinicopathological parameteres and possible epigenetic regulations. Anticancer Res., 2015, 35(11), 6127-6136.
[PMID: 26504039]
[52]
Ye, J.; Mancuso, A.; Tong, X.; Ward, P.S.; Fan, J.; Rabinowitz, J.D.; Thompson, C.B. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. USA, 2012, 109(18), 6904-6909.
[http://dx.doi.org/10.1073/pnas.1204176109] [PMID: 22509023]
[53]
Rajesh, K.; Krishnamoorthy, J.; Kazimierczak, U.; Tenkerian, C.; Papadakis, A.I.; Wang, S.; Huang, S.; Koromilas, A.E. Phosphorylation of the translation initiation factor eIF2α at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death Dis., 2015, 6, e1591.
[http://dx.doi.org/10.1038/cddis.2014.554] [PMID: 25590801]
[54]
Shimura, M.; Mizuma, M.; Takadate, T.; Katoh, Y.; Suzuki, T.; Iseki, M.; Hata, T.; Aoki, S.; Suzuki, Y.; Sakata, N.; Ohtsuka, H.; Hayashi, H.; Morikawa, T.; Nakagawa, K.; Motoi, F.; Naitoh, T.; Igarashi, K.; Sasano, H.; Unno, M. A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget, 2018, 9(36), 24291-24303.
[http://dx.doi.org/10.18632/oncotarget.25110] [PMID: 29849941]
[55]
Matsuda, H.; Parsons, M.J.; Leach, S.D. Aldh1-expressing endocrine progenitor cells regulate secondary islet formation in larval zebrafish pancreas. PLoS One, 2013, 8(9), e74350.
[http://dx.doi.org/10.1371/journal.pone.0074350] [PMID: 24147152]
[56]
Li, J.; Feng, Z.C.; Yeung, F.S.; Wong, M.R.; Oakie, A.; Fellows, G.F.; Goodyer, C.G.; Hess, D.A.; Wang, R. Aldehyde dehydrogenase 1 activity in the developing human pancreas modulates retinoic acid signalling in mediating islet differentiation and survival. Diabetologia, 2014, 57(4), 754-764.
[http://dx.doi.org/10.1007/s00125-013-3147-y] [PMID: 24374552]
[57]
Alkatout, I.; Friemel, J.; Sitek, B.; Anlauf, M.; Eisenach, P.A.; Stühler, K.; Scarpa, A.; Perren, A.; Meyer, H.E.; Knoefel, W.T.; Klöppel, G.; Sipos, B. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod. Pathol., 2015, 28(1), 69-79.
[http://dx.doi.org/10.1038/modpathol.2014.82] [PMID: 24947143]
[58]
Pastorino, J.G.; Hoek, J.B. Regulation of hexokinase binding to VDAC. J. Bioenerg. Biomembr., 2008, 40(3), 171-182.
[http://dx.doi.org/10.1007/s10863-008-9148-8] [PMID: 18683036]
[59]
Shoshan-Barmatz, V.; Mizrachi, D. VDAC1: From structure to cancer therapy. Front. Oncol., 2012, 2, 164.
[http://dx.doi.org/10.3389/fonc.2012.00164] [PMID: 23233904]
[60]
Boutros, R.; Fanayan, S.; Shehata, M.; Byrne, J.A. The tumor protein D52 family: Many pieces, many puzzles. Biochem. Biophys. Res. Commun., 2004, 325(4), 1115-1121.
[http://dx.doi.org/10.1016/j.bbrc.2004.10.112] [PMID: 15555543]
[61]
Lewis, J.D.; Payton, L.A.; Whitford, J.G.; Byrne, J.A.; Smith, D.I.; Yang, L.; Bright, R.K. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol. Cancer Res., 2007, 5(2), 133-144.
[http://dx.doi.org/10.1158/1541-7786.MCR-06-0245] [PMID: 17314271]
[62]
Pfoh, R.; Lacdao, I.K.; Saridakis, V. Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr. Relat. Cancer, 2015, 22(1), T35-T54.
[http://dx.doi.org/10.1530/ERC-14-0516] [PMID: 25605410]
[63]
Jang, M.J.; Baek, S.H.; Kim, J.H. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett., 2011, 302(2), 128-135.
[http://dx.doi.org/10.1016/j.canlet.2011.01.006] [PMID: 21310527]
[64]
Wang, W.J.; Li, Q.Q.; Xu, J.D.; Cao, X.X.; Li, H.X.; Tang, F.; Chen, Q.; Yang, J.M.; Xu, Z.D.; Liu, X.P. Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells. Int. J. Oncol., 2008, 33(5), 1037-1045.
[PMID: 18949367]
[65]
Kleiman, D.A.; Beninato, T.; Sultan, S.; Crowley, M.J.; Finnerty, B.; Kumar, R.; Panarelli, N.C.; Liu, Y.F.; Lieberman, M.D.; Seandel, M.; Evans, T.; Elemento, O.; Zarnegar, R.; Fahey, T.J., III Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann. Surg. Oncol., 2014, 21(Suppl. 4), S672-S679.
[http://dx.doi.org/10.1245/s10434-014-3787-2] [PMID: 24854489]
[66]
Song, Y.L.; Yu, R.; Qiao, X.W.; Bai, C.M.; Lu, C.M.; Xiao, Y.; Zhong, D.R.; Chen, J.; Zhao, Y.P.; Zhang, T.P.; Song, T.T.; Gao, H.L.; Wan, Y.H.; Shen, L.; Chen, J.; Lv, B.; Hao, J.J.; Zhang, Y.; Tang, L.; Chen, Y.J. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. Sci. Rep., 2017, 7(1), 2205.
[http://dx.doi.org/10.1038/s41598-017-02051-1] [PMID: 28526880]
[67]
Kay, R.G.; Challis, B.G.; Casey, R.T.; Roberts, G.P.; Meek, C.L.; Reimann, F.; Gribble, F.M. Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. Rapid Commun. Mass Spectrom., 2018, 32(16), 1414-1424.
[http://dx.doi.org/10.1002/rcm.8183] [PMID: 29857350]
[68]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[69]
Solis-Hernandez, M.P.; Fernandez Del Valle, A.; Carmona-Bayonas, A.; Garcia-Carbonero, R.; Custodio, A.; Benavent, M.; Alonso Gordoa, T.; Nuñez-Valdovino, B.; Sanchez Canovas, M.; Matos, I.; Alonso, V.; Lopez, C.; Viudez, A.; Izquierdo, M.; Calvo-Temprano, D.; Grande, E.; Capdevila, J.; Jimenez-Fonseca, P. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: Comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br. J. Cancer, 2019, 121(7), 537-544.
[http://dx.doi.org/10.1038/s41416-019-0558-7] [PMID: 31477779]
[70]
Lee, L.; Ito, T.; Jensen, R.T. Imaging of pancreatic neuroendocrine tumors: Recent advances, current status, and controversies. Expert Rev. Anticancer Ther., 2018, 18(9), 837-860.
[http://dx.doi.org/10.1080/14737140.2018.1496822] [PMID: 29973077]
[71]
Lee, L.; Ito, T.; Jensen, R.T. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: Recent advances and controversies. Expert Rev. Anticancer Ther., 2019, 19(12), 1029-1050.
[http://dx.doi.org/10.1080/14737140.2019.1693893] [PMID: 31738624]
[72]
Modlin, I.M.; Oberg, K.; Taylor, A.; Drozdov, I.; Bodei, L.; Kidd, M. Neuroendocrine tumor biomarkers: Current status and perspectives. Neuroendocrinology, 2014, 100(4), 265-277.
[http://dx.doi.org/10.1159/000368363] [PMID: 25300695]
[73]
Modlin, I.M.; Kidd, M.; Malczewska, A.; Drozdov, I.; Bodei, L.; Matar, S.; Chung, K.M. The clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol. Metab. Clin. North Am., 2018, 47(3), 485-504.
[http://dx.doi.org/10.1016/j.ecl.2018.05.002] [PMID: 30098712]
[74]
Capdevila, J.; Casanovas, O.; Salazar, R.; Castellano, D.; Segura, A.; Fuster, P.; Aller, J.; García-Carbonero, R.; Jimenez-Fonseca, P.; Grande, E.; Castaño, J.P. Translational research in neuroendocrine tumors: Pitfalls and opportunities. Oncogene, 2017, 36(14), 1899-1907.
[http://dx.doi.org/10.1038/onc.2016.316] [PMID: 27641330]

Rights & Permissions Print Cite
Article Metrics
32
© 2024 Bentham Science Publishers | Privacy Policy